Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.57 |
| ▸ | TDO2 | P48775 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730332 | 0.81 | IDO1 (0.63) | IDO1TDO2ALDH1A1 | |
| SCHEMBL4730877 | 0.80 | IDO1 (0.62) | IDO1TDO2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4727694 | 0.80 | MEN1 (0.48) | RXRARXRBRXRGMAOBNPC1 | |
| SCHEMBL4727691 | 0.80 | MEN1 (0.48) | RXRARXRBRXRGMAOBNPC1 | |
| SCHEMBL14214458 | 0.77 | MEN1 (0.46) | RXRARXRBRXRGMAOBNPC1 | |
| SCHEMBL4726652 | 0.76 | IDO1 (0.56) | IDO1TDO2 | |
| SCHEMBL4980156 | 0.76 | IDO1 (0.61) | IDO1TDO2 | |
| SCHEMBL2387082 | 0.75 | MAOB (0.56) | MAOBNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5631396 | 0.72 | IDO1 (0.62) | IDO1TDO2 | |
| SCHEMBL4729800 | 0.72 | IDO1 (0.55) | IDO1TDO2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-22 | — | — | US | claimed |
| WO-2008036643-A2 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | IDO1 1/4885TDO2 10/4885RXRA 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.